一份开源制药路线图。
An open source pharma roadmap.
作者信息
Balasegaram Manica, Kolb Peter, McKew John, Menon Jaykumar, Olliaro Piero, Sablinski Tomasz, Thomas Zakir, Todd Matthew H, Torreele Els, Wilbanks John
机构信息
Médecins Sans Frontières, Geneva, Switzerland.
Department of Pharmaceutical Chemistry, Philipps-University Marburg, Marburg, Germany.
出版信息
PLoS Med. 2017 Apr 18;14(4):e1002276. doi: 10.1371/journal.pmed.1002276. eCollection 2017 Apr.
Abstract
In an Essay, Matthew Todd and colleagues discuss an open source approach to drug development.
摘要
在一篇文章中，马修·托德及其同事讨论了药物研发的开源方法。
相似文献
1
An open source pharma roadmap.一份开源制药路线图。
PLoS Med. 2017 Apr 18;14(4):e1002276. doi: 10.1371/journal.pmed.1002276. eCollection 2017 Apr.
2
Competition: Unlikely partnerships.竞争：不太可能的伙伴关系。
Nature. 2016 May 12;533(7602):S56-8. doi: 10.1038/533S56a.
3
Q&A: Bernard Munos.问答：伯纳德·穆诺斯
Nature. 2016 May 12;533(7602):S59. doi: 10.1038/533S59a.
4
China spurs pharma innovation.中国推动制药创新。
Nat Rev Drug Discov. 2010 Aug;9(8):581-2. doi: 10.1038/nrd3238.
5
How should we support pharmaceutical innovation?我们应该如何支持药物创新？
Expert Rev Pharmacoecon Outcomes Res. 2009 Aug;9(4):313-20. doi: 10.1586/erp.09.34.
6
Busting the billion-dollar myth: how to slash the cost of drug development.打破十亿美元神话：如何大幅削减药物研发成本。
Nature. 2016 Aug 25;536(7617):388-90. doi: 10.1038/536388a.
7
Increase in R&D openness to tackle disease in the developing world.
Future Med Chem. 2012 Dec;4(18):2237. doi: 10.4155/fmc.12.195.
8
Bailing out.摆脱困境；救助
Genome Biol. 2011 Oct 29;12(10):131. doi: 10.1186/gb-2011-12-10-131.
9
Precompetitive consortia in biomedicine--how are we doing?生物医学领域的赛前联盟——我们做得如何？
Nat Biotechnol. 2013 Nov;31(11):979-85. doi: 10.1038/nbt.2731.
引用本文的文献
1
Combating Antimicrobial Resistance: Role of Key Stakeholders with Focus on the Pharmaceutical Sector.抗击抗菌药物耐药性：关键利益相关者的作用，重点关注制药行业。
Pharmaceut Med. 2025 Jul 11. doi: 10.1007/s40290-025-00572-z.
2
Target 2035 - an update on private sector contributions.《2035年目标——私营部门贡献情况更新》
RSC Med Chem. 2023 Mar 16;14(6):1002-1011. doi: 10.1039/d2md00441k. eCollection 2023 Jun 22.
3
Open source surgical fracture table for digitally distributed manufacturing.开源手术骨折台，用于数字化分布式制造。
PLoS One. 2022 Jul 15;17(7):e0270328. doi: 10.1371/journal.pone.0270328. eCollection 2022.
4
Low-cost anti-mycobacterial drug discovery using engineered E. coli.利用工程化大肠杆菌进行低成本抗分枝杆菌药物发现
Nat Commun. 2022 Jul 7;13(1):3905. doi: 10.1038/s41467-022-31570-3.
5
There is no market for new antibiotics: this allows an open approach to research and development.新抗生素没有市场：这使得在研发方面可以采取开放的方法。
Wellcome Open Res. 2021 Jun 11;6:146. doi: 10.12688/wellcomeopenres.16847.1. eCollection 2021.
6
Madurella mycetomatis causing eumycetoma medical treatment: The challenges and prospects.引起足菌肿的马杜拉分支菌的医学治疗：挑战与前景。
PLoS Negl Trop Dis. 2020 Aug 27;14(8):e0008307. doi: 10.1371/journal.pntd.0008307. eCollection 2020 Aug.
7
Anthelmintic drug discovery: target identification, screening methods and the role of open science.抗寄生虫药物发现：靶点识别、筛选方法及开放科学的作用
Beilstein J Org Chem. 2020 Jun 2;16:1203-1224. doi: 10.3762/bjoc.16.105. eCollection 2020.
8
Six Laws of Open Source Drug Discovery.开源药物研发的六大法则。
ChemMedChem. 2019 Nov 6;14(21):1804-1809. doi: 10.1002/cmdc.201900565. Epub 2019 Oct 15.
9
An analysis and metric of reusable data licensing practices for biomedical resources.生物医学资源可重用数据许可实践的分析与度量。
PLoS One. 2019 Mar 27;14(3):e0213090. doi: 10.1371/journal.pone.0213090. eCollection 2019.
10
Ideation and implementation of an open science drug discovery business model - M4K Pharma.开放科学药物发现商业模式的构思与实施——M4K制药公司
Wellcome Open Res. 2018 Dec 6;3:154. doi: 10.12688/wellcomeopenres.14947.1. eCollection 2018.
本文引用的文献
1
Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles.开源药物发现：源自特雷斯坎托斯芳基吡咯的高效抗疟化合物。
ACS Cent Sci. 2016 Oct 26;2(10):687-701. doi: 10.1021/acscentsci.6b00086. Epub 2016 Sep 14.
2
A second look: Efforts to repurpose old drugs against Zika cast a wide net.再度审视：重新利用旧药对抗寨卡病毒的努力范围广泛。
Nat Med. 2016 Aug 4;22(8):824-5. doi: 10.1038/nm0816-824.
3
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.利用疟疾盒化合物库开展针对被忽视疾病及其他疾病的开源药物研发。
PLoS Pathog. 2016 Jul 28;12(7):e1005763. doi: 10.1371/journal.ppat.1005763. eCollection 2016 Jul.
4
Best practices for sharing information through data platforms: establishing the principles.通过数据平台共享信息的最佳实践：确立原则
Bull World Health Organ. 2016 Apr 1;94(4):234-234A. doi: 10.2471/BLT.16.172882.
5
Open innovation platforms to boost pharmaceutical collaborations: evaluating external compounds for desired biological activity.开放创新平台促进制药合作：评估外部化合物的预期生物活性。
Future Med Chem. 2015;7(14):1853-9. doi: 10.4155/fmc.15.122. Epub 2015 Sep 22.
6
The promise and peril of chemical probes.化学探针的前景与风险
Nat Chem Biol. 2015 Aug;11(8):536-41. doi: 10.1038/nchembio.1867.
7
Open access target validation is a more efficient way to accelerate drug discovery.开放获取的靶点验证是加速药物研发的更有效方式。
PLoS Biol. 2015 Jun 4;13(6):e1002164. doi: 10.1371/journal.pbio.1002164. eCollection 2015 Jun.
8
2015 Alzheimer's disease facts and figures.2015 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2015 Mar;11(3):332-84. doi: 10.1016/j.jalz.2015.02.003.
9
Time for a change: addressing R&D and commercialization challenges for antibacterials.变革之时：应对抗菌药物研发与商业化挑战
Philos Trans R Soc Lond B Biol Sci. 2015 Jun 5;370(1670):20140086. doi: 10.1098/rstb.2014.0086.
10
Opening up clinical study design to the long tail.
Sci Transl Med. 2014 Oct 1;6(256):256ed19. doi: 10.1126/scitranslmed.3009116.
Zotero 插件